Triple uptake inhibitors: Therapeutic potential in depression and beyond

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1365-1377

  Chen, Zhengming ^a   Skolnick, Phil ^a  

^a DOV Pharmaceutical Inc   (United States)

Author keywords

Antidepressant; Depression; Drug design; Dual uptake inhibitors; Monoamine uptake inhibitor; SDRAI; SNRI; SSRI; SSRI SNRI; Structure activity relationship; Synthesis; Tricyclic antidepressant; Triple uptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; BIOGENIC AMINE; CLOMIPRAMINE; DESIPRAMINE; DEXMETHYLPHENIDATE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DOXEPIN; DULOXETINE; FLUOXETINE; IMIPRAMINE; IPRONIAZID; METHYLPHENIDATE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENOTHIAZINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; SYMBALTA; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER UPTAKE INHIBITOR; SEROTONIN ANTAGONIST;

CLINICAL TRIAL; DEPRESSION; DRUG BINDING; DRUG CHOICE; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG UPTAKE; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; LONG TERM CARE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PATIENT COMPLIANCE; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; ANIMAL; CLASSIFICATION; DRUG ANTAGONISM; METABOLISM; PSYCHOLOGICAL ASPECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOPAMINE ANTAGONISTS; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; SEROTONIN ANTAGONISTS;

EID: 34548547156     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1365     Document Type: Review

References (53)

1. THASE ME: Treatment of severe depression. J. Clin. Pharmacol. (2000) 61:17-25.
2. KESSLER RC, BERGLUND P, DEMLER O et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 289:3095-3105.
3. NEMEROFF CB: The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J. Psychiatry Res. (2007) 41:189-206.
4. GELENBERG AJ, HOPKINS HS: Assessing and treating depression in primary care medicine. Am. J. Med. (2007) 120:105-108.
5. ULUS IH, MAHER TJ, WURTMAN RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Bio. Pharmacol. (2000) 59(12):1611-1621.
6. BAN TA. The role of serendipity in drug discovery. Dialogues Clin. Neurosci. (2006) 8(3):335-344.
7. KUHN R: Treatment of depressive states with an iminodibenzyl derivative (G 22355). Schweiz Med. Wochenschr. (1957) 87(35-36):1135-1140.
8. KUHN R: The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry (1958) 115(5):459-464.
9. FAZIO C, GIBERTI F, LOEB C: A new drug (iminodibenzylic derivative, G 22355) in therapy of depressive states. Minerva Med. (1958) 49(65-66):3143-3148.
10. LEMBERGER L, ROWE H, CARMICHAEL R et al.: Pharmacologic effects in man of a specific serotonin-uptake inhibitor. Science (1978) 199(4327):436-437.
11. WONG DT, PERRY KW, BYMASTER FP: Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat. Rev. Drug Discov. (2005) 4(9):764-774.
12. WONG DT, BYMASTER FP: Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants - potential for greater efficacy or just hype? Prog. Drug Res. (2002) 58:169-222.
13. STAHL SM, GRADY MM, MORET C, BRILEY M: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. (2005) 10(9):732-747.
14. LOPEZ-IBOR J, GUELFI JD, PLETAN Y. TOURNOUX A, PROST JF: Milnacipran and selective serotonin uptake inhibitors in major depression. Int. Clin. Psychopharmacol. (1996) 11(4):41-46.
15. VAISHNAVI SN, NEMEROFF CB, PLOTT SJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Bio. Psychiatry (2004) 55(3):320-322.
16. ECKERT L, LANCON C: Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry (2006) 6:30.
17. MARKOWITZ JS, DEVANE L, PESTREICH LK, PATRICK KS, MUNIZ R: A comprehensive in vitro screening of D-, L-, and D,Lthreo-methylphenidate: an exploratory study. J. Child Adolesc. Pychopharmacol. (2006) 16(6):687-698.
18. BAN TA. Pharmacotherapy of depression: a historical analysis. J. Neural Trans. (2001) 108(6):707-716.
19. BYMASTER FP, MCNAMARA RK, TRAN PV: New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin. Investig. Drugs (2003) 12(4):531-543.
20. HOLTZHEIMER PE III, NEMEROFF CB: Emerging treatments for depression. Expert Opin. Pharmacother. (2006) 7(17):2323-2339.
21. PAUL IA: Excitatory amino acid signalling, major depression and the actions of antidepressants. Pharmaceut. News (2001) 8:33-44.
22. NIERENBERG AA, AMSTERDAM JD: Treatment-resistant depression: definition and treatment approaches. J. Clin. Psychiatry (1990) 51(Suppl.):39-47; Discussion 48-50.
23. O'REARDON JP, AMSTERDAM JD: Treatment-resistant depression: progress and limitations. Psychiatr. Annals (1998) 28(11):633-640.
24. TRIVEDI MH, RUSH AJ, WISNIEWSKI SR et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry (2006) 163:28-40.
25. NIERENBERG AA, QUITKIN FW, KREMER C, KELLER MB, THASE ME: Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology (2004) 29(5):1012-1018.
26. SKOLNICK P, BASILE AS: Triple uptake inhibitors as antidepressants. Drug Discov. Today Ther. Strategies (2006) 3:489-494.
27. SKOLNICK P, BASILE AS: Triple uptake inhibitors ('broad spectrum' antidepressants). CNS Neurol. Disord. Drug Targets (2007) 6:000-000.
28. SKOLNICK P, POPIK P, JANOWSKY A, BEER B, LIPPA AS: 'Broad spectrum' antidepressants: is more better for the treatment of depression? Life Sci. (2003) 73(25):3175-3179.
29. PAPAKOSTAS GI: Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol. (2006) 16:391-402.
30. FAVA M: Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry (2001) 62 (Suppl. 18):4-11.
31. TRIVEDI MH, FAVA M, WISNIEWSKI SR et al.: Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. (2006) 354:1243-1252.
32. SKOLNICK P, KRIETER P, TIZZANO J et al.: Preclinical and clinical pharmacology of DOV 216,303, a 'triple' uptake inhibitor. CNS Drug Rev. (2006) 12:123-134.
33. SKOLNICK P, POPIK P, JANOWSKY A, BEER B, LIPPA AS: Antidepressant-like actions of DOV 21,947: a 'triple' uptake inhibitor. Eur. J. Pharmacol. (2003) 461(2-3):99-104.
34. POPIK P, KRAWCZYK M, GOLEMBIOWSKA K et al.: Pharmacological profile of die 'triple' monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell. Mol. Neurobiol. (2006) 26(4-6):857-873.
35. BEER B, STARK J, KRIETER P et al.: DOV 216,303, a 'triple' uptake inhibitor. safety, tolerability, and pharmacokinetic profile. J. Clin. Pharmacol, (2004) 44(12):1360-1367.
36. AMRI Press Release, Albany (24 October 2005).
37. AMRI Drug Discovery Symposium (October 2006).
38. AMRI Press Release, Albany (11 June 2007).
39. ZHOU J, HE R, JOHNSON KM, YE Y, KOZIKOWSKI AP: Piperidine-based nocaine/ modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J. Med. Chem. (2004) 47:5821-5824.
40. ZHOU J, JOHNSON KM, GIBERSON KM, MCGONIGLE P, CALDARONE BJ, KOZIKOWSKI AP: Development of nocaine/modafinil hybrid monoamine transporter inhibitors as superior antidepressants: from compound library establishment to in vivo evaluation. 232nd American Chemical Society National Meeting and Exposition. San Francisco, (10 - 14 September 2006):MEDI9.
41. CARLIER PR, LO MMC, LO PCK et al.: A. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-uptake inhibitor (SNDRI) and a species-selective dopamine-uptake inhibitor based on the γ-amino alcohol functional group. Bioorg. Med. Chem. Lett. (1998) 8:487-492.
42. SHAW AM, BOULES M, ZHANG Y et al.: Antidepressant-like effects of novel triple uptake inhibitors, PRC025 and PRC050. Eur. J. Pharmacol. (2007) 555:30-36.
43. AXFORD L, BOOT JR, HOTTEN TM et al.: Bicyclo [2.2.1] heptanes as novel triple re-uptake inhibitors for the treatment of depression. Bioorg. Med. Chem. Lett. (2003) 13:3277-3280.
44. Medicinal Chemistry in Eastern England - 14th Symposium (2003).
45. CASES M, MASTERS JJ, HAUGHTON L et al.: Synthesis and discovery 3-amino piperidine and pyrolidine-based inhibitors of neurotransmitter re-uptake transporters. 230th American Chemical Society National Meeting & Exposition. Washington, DC, USA (28 August - 1 September 2005).
46. YU H, KIM IJ, FOLK JE et al.: Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J. Med. Chem. (2004) 47:2624-2634.
47. ENYEDY IJ, ZAMAN WA, SAKAMURI S, KOZIKOWSKI AP, JOHNSON KM, WANG S: Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:1113-1118.
48. SAKAMURI S, ENYEDY IJ, KOZIKOWSKI AP, ZAMAN WA, JOHNSON KM, WANG S: Pharmacophore-based discovery, synthesis, and biological evaluation of 4-phenyl-1-arylalkyl piperidines as dopamine transporter inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:495-500.
49. HOULIHAN WJ, KELLY L, PANKUCH J et al.: Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J. Med. Chem. (2002) 45:4097-4109.
50. HOULIHAN WJ, AHMAD UF, KOLETAR J, KELLY L, BRAND L, KOPAJTIC TA: Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J. Med. Chem. (2002) 45:4110-4118.
51. ZRANG S, FERNANDEZ F, HAZELDINE S et al.: Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-terrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters. J. Med. Chem. (2006) 49:4239-4247.
52. ZHANG S, ZHEN J, REITH MEA, DUTTA AK: Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner. J. Med. Chem. (2005) 48:4962-4971.
53. CHEN Z, YANG J, SKOLNICK P: The design, synthesis and SAR of new antidepressants. Strategy Research Institute. CNS Diseases Congress. Boston, MA, USA (27 - 28 March 2006).